Dual-Targeting CSC Therapy: Acid-Responsive Cisplatin/CaCO₃@siRNA Nanoplatform Overcomes HCC Chemoresistance.

ABSTRACT: Background: Cisplatin resistance is a major obstacle in the treatment of Hepatocellular carcinoma (HCC), characterized by reduced intracellular drug accumulation and altered DNA repair/apoptosis signaling. Methods: To address this challenge, we developed an acid-responsive nanoplatform consisting of a cisplatin-loaded CaCO₃ core with a lipid coating that enables surface adsorption of Bmi1 siRNA, termed LCa/C@B. Results: These nanoparticles are subsequently coated with positively charged phospholipids, facilitating the absorption of Bmi1 siRNA. In vitro, LCa/C@B markedly enhanced intracellular cisplatin accumulation, downregulated Bmi1 and cancer stem cell (CSC) markers, and restored chemosensitivity in HepG2/MDR cells. In vivo, LCa/C@B achieved improved tumo

SUBMITTER: Wang F 

PROVIDER: S-EPMC12845244 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature